yea I see that. JNJ up again as usual. Ho Hum .How tiny is that company you're talking about ? I not giving you a thumbs down.....you have enough.
The EMA had already acknowledged that it views Arikayce as a safer and more effective version of intravenous amikacin -
[ The sponsor presented early clinical data showing better lung penetration and lower incidence of side effects as compared to the existing intravenous formulation. The Committee considered that this can translate into a clinically relevant advantage for patients affected by nontuberculous mycobacterial lung disease, as there are well-known and documented side-effects of the existing intravenous formulation that limit its use. ]
The FDA had previously accepted Phase II culture conversion data, when it approved bedaquiline for MDR-TB subject to a post-approval study.
In approving bedaquiline the FDA even saw fit to overlook (but for a Black Box warning) an unexplained significantly higher mortality rate in the bedaquiline arm to the placebo arm (9 of 79 patients vs 2 of 81 patients) with the following rationale -
[ Nonetheless, treatment for resistant TB is complex, costly, toxic and prolonged, requiring at least 5 second-line drugs for up to 2 years. Second-line drugs include injectable drugs (amikacin, kanamycin, capreomycin) and oral fluoroquinolones (FQs) and other second line drugs; the optimal use of which has not been well studied in randomized controlled trials, and whose safety when used in concert with various doses and regimens is not sufficiently described. ]
Given the importance to the FDA of the unquantified risk posed by co-administration of multiple drugs - including intravenous amikacin - in resistant Tuberculosis, surely it must have been obvious that a therapy which has now delivered amikacin safely and effectively to -
Mycobacterium Avium Complex infection and
Mycobacterium Abscessus infection
- is "reasonably likely" to improve a "toxic and prolonged" antibiotic regimen for Mycobacterium Tuberculosis infection, by eliminating the documented side-effects of kidney damage and loss of hearing?
If the government's plan for getting people back to work is to
incentivize NOT working, with 99 weeks of unemployment checks and no
requirement to prove they applied but can't find work, you live in a country run by idiots like Pelosi, Reid, Obama.
Instead of giving me thumbs down, why don't you take a few minutes and read the facts. JNJ makes around $40 million dollar per day (give or take)....everyday in Net Income. For basically a week or so of 'work', JNJ could acquire a company that makes a superior diabetic test strip that costs the consumer less. Imagine the public backlash and government pressure that JNJ would face if they were found guilty in the court of public opinion of overcharging and price gouging senior citizens and diabetics throughout the world....
Now look at it from the capitalism point of view....they could spend a week or so worth of 'work' and buy DECN. Have DECN's Genstrip be the private label and have the LifeScan be the premium brand. This is standard CPG stuff here....Then, they could turn the DECN team loose on cracking all the patents of Bayer and Roche and every other supplier in the market place.....or they could make a deal with all their major customers and retailers that they have to take both the Genstrip and Lifescan strip and eliminate another competitor from the shelf. Or they could buy DECN and do nothing with it....and continue to make a premium on LifeScan strips for a short period of time (profits would trump the small acquisition costs)
The possibilities are nearly endless....yet JNJ continues to step over a dollar to fight for a dime. Are your calculators turned off or broken? This is easy math here guys. A company with a market cap of $10-$20 million is costing you tens of millions in legal fees and a potential loss of hundreds of millions in profits. It is called managing risk.
Look at the bigger picture and build some shareholder value! That's what Management gets paid for.
Full Disclosure: I am a shareholder of JNJ and DECN because the marriage makes sense.
PLWY enters the video messaging space with latest software rights acquisition. Management bullish on the potential of software and plans to do aggressive marketing
Another court date last Friday and again....JNJ playing from behind. Sooner or later JNJ will have to acquire and/or pay a hefty fine to DECN. This is good news for all shareholders. JNJ needs to do the right thing for their company, customers and diabetics around the world and provide diabetics the option for a LifeScan strip and/or a Genstrip to use with a LifeScan device.
Ignore is a good idea.
Why is she pumping such a large cap stock?
Is she simply trying to convince herself that she made the right trade?
She sure like to laugh a lot--rather bizarre.
I get that GSK yield significantly more than JNJ.
Do you get that you posted inaccurate info re the two companies' RSIs???
look like Buffett is cutting down big on JNJ
Johnson & Johnson (NYSE: JNJ) was the same tiny stake of only 327,100 shares, but this much lower than years past.
Major Portfolio Changes for Warren Buffett and Berkshire Hathaway -
On August 11 the Company guided in a preliminary prospectus that it intended to issue "up to $80,000,000 of shares" - with underwriters having an option to purchase an additional $12,000,000 of shares within 30 days.
On August 18 the Company announced it had issued $115,143,750 of shares - including the option, exercised in full - at $11.25 per share.
From the 18th to the 20th the share price didn't drop below $13.31 - and was $13.50 or above most of the time.
Doesn't that seem unusually generous - giving investors who bought ten million shares in the Offering the opportunity to bank an immediate profit of 20%?
The Company now has sufficient cash to fund operations at the current burn rate until the second half of 2016.
Barring a problem with the application for marketing authorisation Arikayce is due to be launched in Europe in the second half of 2015.
Friday's closing price of $13.15 x 49,511,389 shares gives a present valuation of $651,074,765.
12,000 patients x $30,000 would generate annual sales of $360,000,000.
A multiple of 18.09 would deliver a valuation of $6,512,400,000.
How likely is it that physicians treating at least 12,000 of the 12,000,000 infected Worldwide will be able to substitute Arikayce for one (or more) of the antibiotics contributing to the toxicity of the current regimens for normal TB and MDR-TB?
Analysts? No, I certainly don't trust professional analysts. I make ALL my investment decisions based on advice posted on message boards by shorts and pumpers. Look, I'm happy that you're happy, so just keep on with whatever it is you're trying to do. I'm putting you on IGNORE now, so you won't get any more responses from me. Good luck with GSK.
Read this again...& again..lol
"For investors, this is great news. Indeed, the one-off payout, combined with Glaxo’s current yield of 5.3%, implies that investors are in line to receive a yield of around 10% next year."
and one more...lol
GlaxoSmithKline: ViiV Healthcare receives FDA approval for Triumeq (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection (GSK) : ViiV Healthcare announced that the FDA has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor dolutegravir, with the nucleoside reverse transcriptase inhibitors abacavir and lamivudine.
Phase III study (:SINGLE) of treatment-na ve adults, conducted with dolutegravir and abacavir/lamivudine as separate pills.
A bioequivalence study of the fixed-dose combination of abacavir, dolutegravir and lamivudine when taken as a single pill compared to the administration of dolutegravir and abacavir/lamivudine as separate pills.
At 96 weeks, 80% of participants on the dolutegravir-based regimen were virologically suppressed compared to 72% of participants on Atripla.
ViiV Healthcare is a joint venture with 76.5% controlled by GlaxoSmithKline (GSK), 13.5% controlled by Pfizer (PFE), and 10% controlled by Shionogi.
just to complete my trading....deal......
i sold 500 JNJ at $102.90 on aug 19 and bought 1095 GSK....
You follow...before that I was getting 500x$2.80 dividend/year=$1400 with JNJ
Now I will get 1095X $2.65=$2901.75 & $1.34 per shares (extra -dividendes for NVS-Deal) in 2015
add 1095 x$1.34 special B-shares dividend for 2015=$1467.30 extra
total: GSK will give me $2900 & 1467.30 =$4367 dividend....and with that i could buy some more shares of GSK or JNJ when they are cheaper...lol
Now you know what is the reason i trade it....lol
well if 13 analysts follow JNJ seriously and say buy at $104......lkeep buying....i'm selling....if Cramer tell you to Buy JNJ at $104...You must buy too??
Unreal?? peoples still trust analysts???
I would follow the analyst who said sell JNJ at 52 weeks high...lol
now for GSK....if you follow Yahoo finance for your numbers...lol
on Nasdaq you get this dividend....$2.65 not $2,56 ??
Ex/Eff Date Type Cash Amount Declaration Date Record Date Payment Date
8/6/2014 Cash 0.648204 7/23/2014 8/8/2014 10/2/2014
5/14/2014 Cash 0.640034 4/30/2014 5/16/2014 7/10/2014
2/19/2014 Cash 0.749616 2/5/2014 2/21/2014 4/10/2014
11/13/2013 Cash 0.616094 10/23/2013 11/15/2013 1/9/2014
$2.65 /$47.68=5.555788 or 5.6% as of today....i bought @$47 so i have 5.66% yield